

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

WATSON PHARMACEUTICALS, INC. (NEW JERSEY)

2. Address:

1420 NEW YORK AVENUE, N.W. SUITE 700, WASHINGTON, DC 20005

3. Principal place of business (if different from line 2):

Country: City: CORONA State/Zip(or Country): CA 92880

4. Contact Name: G. THOMAS LONG

Telephone: 202-393-1220

E-mail (optional): tom.long@watsonpharm.com

Senate ID #: 63837-12

House ID #: 35518000

7. Client Name: ☒ Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Expenses (nearest \$20,000): 580,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☒ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: WATSON PHARMACEUTICALS, INC. (NEW JERSEY) Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

H.R. 5384 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations for FY 2007: FDA (OGD). S. 1932 Deficit Reduction Omnibus Reconciliation Act of 2005 (Medicare and Medicaid provisions).

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services

US HOUSE OF REPRESENTATIVES

US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Registrant Name: WATSON PHARMACEUTICALS, INC. (NEW JERSEY) Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

H.R. 2795 Patent Reform Act of 2005 Various biodefense and vaccine and drug development bills including: S. 3, S. 975, H.R. 2795, S. 2564, S. 1873, and S. 3678.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Various bills regarding the importation of prescription drugs including: H.R. 328, S. 109, H.R. 700, S. 334, H.R. 753, S. 184, H.R. 5993, S. 3695; legislation to prohibit the marketing of authorized generic drugs. H.R. 2345 Counterfeit Drug Enforcement Act of 2005 H.R. 4829 Reducing Fraudulent and Imitation Drug Act of 2005; S. 2300 Lower PRICED Drug Act Meetings with Members of Congress regarding generic biologics and Food and Drug Administration regulatory activity of interest to the Registrant.

17. House(s) of Congress and Federal agencies contacted:

US HOUSE OF REPRESENTATIVES
US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS
Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WATSON PHARMACEUTICALS, INC. (NEW JERSEY) Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H. R. 1298 and S. 635 Kidney Care Quality and Improvement Act of 2005. Contacts with Members of Congress regarding Centers for Medicare and Medicaid Services (CMS) regulatory activity implementing Medicare Part B changes under the MMA, Medicaid changes under the DRA, and the Part D drug benefit. Contacts with Federal officials re: CMS Part B and Part D regulatory activity.

17. House(s) of Congress and Federal agencies contacted:

Department of Health and Human Services

US HOUSE OF REPRESENTATIVES

US SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: LONG, G. THOMAS

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 14, 2006

Printed Name and Title: G. Thomas Long - Vice President, Government Affairs -

Information Update Page:

Complete ONLY where registration information has changed.

21. Client new principal place of business (if different from line 20):

Country: USA

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 14, 2006

Printed Name and Title: G. THOMAS LONG - VICE PRESIDENT, GOVERNMENT AFFAIR -